Results 1 to 10 of about 42,088 (274)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia

Медицинский совет, 2021
Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva, M. L. Maximov, N. M. Kiseleva   +2 more
doaj   +3 more sources

Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis [PDF]

Lipids in Health and Disease, 2021
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis.
Susanne Feder, Reiner Wiest, Thomas S. Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler   +7 more
doaj   +2 more sources

PCSK9 induces a pro-inflammatory response in macrophages [PDF]

, 2018
Intraplaque release of inflammatory cytokines from macrophages is implicated in atherogenesis by inducing the proliferation and migration of media smooth muscle cells (SMCs). PCSK9 is present and released by SMCs within the atherosclerotic plaque but its
Adorni, Maria Pia, Camera, Marina, Cicero, Arrigo F G, Colciago, Alessandra, Corsini, Alberto, Ferri, Nicola, Fogacci, Federica, LUPO, MARIA GIOVANNA, Macchi, Chiara, Ricci, Chiara, Rossetti, Laura, Ruscica, Massimiliano, Zanotti, Ilaria   +12 more
core   +5 more sources

PCSK9 Gene Polymorphisms Associated With the Risk of Myocardial Infarction in Iranian Patients [PDF]

International Journal of Basic Science in Medicine, 2021
Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulatory protein in lipid metabolism and a candidate gene in the etiology of cardiovascular diseases.
Farshad Namordizadeh, Mahboobeh Nasiri
doaj   +1 more source

PCSK9 is not secreted from mature differentiated intestinal cells

Journal of Lipid Research, 2021
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes lysosomal degradation of the LDL receptor and is a key regulator of cholesterol metabolism. After the liver, the small intestine is the second organ that highly expresses PCSK9.
Moreau François, Aurélie Thédrez, Damien Garçon, Audrey Ayer, Thibaud Sotin, Wieneke Dijk, Claire Blanchard, Gilliane Chadeuf, Lucie Arnaud, Mikael Croyal, Laurianne Van Landeghem, Melissa Touvron, Xavier Prieur, Anna Roubtsova, Nabil Seidah, Annik Prat, Bertrand Cariou, Cedric Le May   +17 more
doaj   +1 more source

PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation

Journal of Lipid Research, 2022
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) regulates the cell-surface localization of LDL receptors in hepatocytes and is associated with LDL and lipoprotein(a) [Lp(a)] uptake, reducing blood concentrations.
Ioannis Dafnis, Aikaterini N. Tsouka, Christina Gkolfinopoulou, Constantinos C. Tellis, Angeliki Chroni, Alexandros D. Tselepis   +5 more
doaj   +1 more source

A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines

Vaccines, 2022
Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation ...
Louise Goksøyr, Magdalena Skrzypczak, Maureen Sampson, Morten A. Nielsen, Ali Salanti, Thor G. Theander, Alan T. Remaley, Willem A. De Jongh, Adam F. Sander   +8 more
doaj   +1 more source

Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. [PDF]

PLoS ONE, 2015
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that directs membrane-bound receptors to lysosomes for degradation. In the most studied example of this, PCSK9 binding leads to the degradation of low density lipoprotein receptor
Rachel M DeVay, Lynn Yamamoto, David L Shelton, Hong Liang   +3 more
doaj   +1 more source

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Biomolecules, 2022
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms.
Arianna Toscano, Maria Cinquegrani, Michele Scuruchi, Antonino Di Pino, Salvatore Piro, Viviana Ferrara, Carmela Morace, Alberto Lo Gullo, Egidio Imbalzano, Francesco Purrello, Giovanni Squadrito, Roberto Scicali, Giuseppe Mandraffino   +12 more
doaj   +1 more source

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome

Frontiers in Medicine, 2022
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells.
Thomas S. Metkus, Bo Soo Kim, Steven R. Jones, Seth S. Martin, Steven P. Schulman, Thorsten M. Leucker   +5 more
doaj   +1 more source